Study shows potential for triple immunotherapy in glioblastoma
An experimental cancer treatment developed by researchers at the Melanoma Institute Australia paves the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne.
It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of three checkpoint inhibitor immunotherapies administered prior to surgery.
The study, which has been published in Nature Medicine, was led by Professor Georgina Long, University of Sydney Medical Oncologist and Medical Director of the Melanoma Institute Australia.
When resected, the tumour treated with immunotherapy showed increased diversity, abundance, and activation of immune cells compared to the tumour prior to receiving immunotherapy.
At the time of final submission of the paper on 9 January 2025, the patient had no clear signs of cancer recurrence after more than 18 months.
“My hypothesis was that we could administer combination immunotherapy as first line treatment before surgery to boost the immune system and activate T-cells to target the brain tumour – an approach I had previously developed successfully in both stage 3 melanoma and melanoma that had spread to the brain,” said Professor Long. “This has never been done before and what this trial will do is establish whether this approach is feasible or effective for the treatment of glioblastoma.”
Large glioblastoma clinical trial
An Australian-led international clinical trial will scientifically investigate the efficacy of the approach within a large cohort of eligible glioblastoma patients and could commence within a year.
It will trial the use of double immunotherapy. In some patients, it will be combined with chemotherapy.
“I am delighted to be handing the baton to Dr Jim Whittle, a leading Australian neuro-oncologist at the Peter MacCallum Cancer Centre, The Royal Melbourne Hospital and Co-Head of Research Strategy at the Brain Cancer Centre to commence a broader scientific study to scientifically determine if – and how – this process might work in treating glioblastoma,” Professor Long added, who also secured drug access for the clinical trial.
“While we are buoyed by the results of this experimental treatment so far, a clinical trial in a large group of patients would need to happen before anyone could consider it a possible breakthrough.”
Diana Spencer, Senior Digital Content Editor, DDW
